Aubagio Dosage/Direction for Use

The treatment should be initiated and supervised by a physician experienced in the management of multiple sclerosis.
Posology: The recommended dose of AUBAGIO is 14 mg once daily.
Special populations: Elderly population: AUBAGIO should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy.
Renal impairment: No dosage adjustment is necessary for patients with mild, moderate or severe renal impairment not undergoing dialysis.
Patients with severe renal impairment undergoing dialysis were not evaluated. Teriflunomide is contraindicated in this population (see Contraindications).
Hepatic impairment: No dosage adjustment is necessary for patients with mild and moderate hepatic impairment. Teriflunomide is contraindicated in patients with severe hepatic impairment (see Contraindications).
Paediatric population: The safety and efficacy of AUBAGIO in children aged from 10 to less than 18 years has not yet been established. There is no relevant use of teriflunomide in children aged from birth to less than 10 years for the treatment of multiple sclerosis.
No data are available.
Method of administration: The film-coated tablets are for oral use. The tablets should be swallowed whole with some water. AUBAGIO can be taken with or without food.